Healthcare Industry News: osteoporosis
News Release - September 28, 2006
Sciele Pharma Introduces OSTIVA(TM), a New Women's Health ProductNew Prescription Nutritional Supplement with Metafolin(R), Calcium, and Vitamin D Gives Women Nutritional Support to Maintain Healthy Bones
ATLANTA--(HSMN NewsFeed)--Sciele Pharma, Inc. (NASDAQ:SCRX ) today announced the introduction of OSTIVA(TM), an oral prescription nutritional supplement formulation with Metafolin®, calcium, and vitamin D that gives women nutritional support to help maintain healthy bones.
OSTIVA(TM) offers a nutritional foundation for maintaining bone health. It contains Metafolin®, an active form of folate, which can aid in reducing elevated homocysteine levels and, by doing so, may lead to healthier bones. OSTIVA(TM) also contains calcium, which can contribute to the development of healthy bones; vitamin D, which helps enhance the absorption of calcium within the body; and magnesium and vitamins B6 and B12, which may contribute to maintaining bone health. Together with regular exercise, a healthy diet, and enough calcium, OSTIVA(TM) can help women take action to reduce the risk of osteoporosis. OSTIVA may be used in conjunction with other products that may require dietary supplementation, such as bisphosphonates.
Patrick Fourteau, Sciele Pharma's President and Chief Executive Officer, said, "We are pleased to launch OSTIVA(TM), an innovative new product especially for women who are unable to completely metabolize folic acid, and it helps maintain bone health. OSTIVA(TM) complements and expands our women's health product portfolio. It is designed to benefit a broad age-range of women, including menopausal and post-menopausal women."
Sciele Pharma, Inc. Background
Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and developing branded prescription products focused on Cardiovascular/Metabolic and Women's Health. The Company's Cardiovascular/Metabolic products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2 diabetes, and its Women's Health products are designed to improve the health and well-being of mothers and their babies. Headquartered in Atlanta, Georgia, and founded in 1992, Sciele employs more than 700 people, including approximately 560 sales representatives. The Company's success is based on placing the needs of patients first, improving health and quality of life and implementing its business platform - an Entrepreneurial Spirit, Innovation, Speed of Execution, Simplicity and Teamwork. For more information about Sciele Pharma and its products, visit www.sciele.com.
Metafolin® is a registered trademark of Merck KGaA, Germany.
Source: Sciele Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.